(Pfizer Animal Health) Slentrol Oral Solution prevents hunger to help obese dogs lose weight. Slentrol contains 5 mg dirlotapide per ml of oral solution. Slentrol acts locally in the gut to reduce appetite, increase fecal fat and produce weight loss in the management of obesity in dogs. A decrease in appetite and associated begging behavior can be expected with treatment. Slentrol should be used as part of an overall weight management program that includes physical activity and a complete, balanced diet. The dose should not exceed a maximum daily dose of 0.2 ml/kg (0.09 ml/lb), based on the dog’s current body weight, during any part of treatment. Dosage adjustments will be determined by weight loss achieved. The decreased appetite experienced when dogs are treated with dirlotapide is only temporary and lasts no longer than 1-2 days beyond the cessation of therapy. Dirlotapide.